HopeStage
Back to all studies
TerminatedNCT00169091

Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia

Medication studyAges 18–45United States
The study in practice

Understand this study

Who could participate?

Listed age limits: 18 years to 45 years.

Listed locations
Jamaica PlainSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateMarch 1996
Recruitment status
Terminated
Enrollment listed in the registry
32
Sponsor
Harvard Medical School (HMS and HSDM)
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United States
Age range
From 18 Years to 45 Years
Official registry ID
NCT00169091
Official title
Show the full official title

Clozapine or Haloperidol in First Episode Schizophrenia

Recruitment & locations

Terminated

Jamaica Plain

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Harvard Medical School (HMS and HSDM).

Does this study involve medication?

Yes. The study involves medication, including Clozapine and Haloperidol.

Who can participate?

Listed age limits: 18 years to 45 years.

Is this study still recruiting?

The registry lists this study as terminated.

Want to explore more studies?

Explore studies